Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Research

    Adding MRI to Prostate Cancer Testing Improves Accuracy, NIH Study Says
    Prostate cancer

    Adding MRI to Prostate Cancer Testing Improves Accuracy, NIH Study Says

    Combining a traditional 12-point biopsy with magnetic resonance imaging (MRI) improves the accuracy of prostate cancer diagnosis, according to findings from a new National Institutes of Health (NIH) study published in the New England Journal of Medicine. 

    March 26, 2020
    Radiation Unnecessary for Children With ALL
    Radiation therapy

    Radiation Unnecessary for Children With ALL

    Children with acute lymphoblastic leukemia (ALL) at risk for cancer recurrence in the brain don’t need prophylactic radiation therapy, researchers reported in the Journal of Clinical Oncology. 

    March 18, 2020
    U.S. Still Has Declining Cancer Death Rates, Latest National Report Says
    Research

    U.S. Still Has Declining Cancer Death Rates, Latest National Report Says

    Overall cancer death rates fell 1.5% on average per year from 2001–2017 in the United States for all cancer sites combined, according to the Annual Report to the Nation on the Status of Cancer from the Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), American Cancer Society, and North American Association of Central Cancer Registries.

    March 16, 2020
    NIDA Calls for Further Cannabis Research in Congress Testimony
    Health Policy

    NIDA Calls for Further Cannabis Research in Congress Testimony

    Medical cannabis has been approved for use in more than 33 states, many of which have decriminalized its use as well, and a health policy wave has spread across the country through state referendums to ease the burden for legalizing cannabis for health purposes. It’s a different world than it was 30 years ago, and the National Institute on Drug Abuse (NIDA) is frequently called to testify before Congress to address concerns and questions from lawmakers.

    March 12, 2020
    PCORI Reauthorization Funds Program Through 2029
    Health Policy

    PCORI Reauthorization Funds Program Through 2029

    Patient-centered research is vital in the effort to move the needle in cancer care, and nurse researchers rely on funding from organizations like the Patient-Centered Outcomes Research Institute (PCORI) to support new and ongoing studies. In December 2019, the U.S. House of Representatives approved the Further Consolidation Appropriations Act, 2020 (H.R. 1865), extending funding for PCORI through fiscal year 2029.

    March 11, 2020
    Oncolytic Virus Kills Tumor Cells While Supporting T Cells
    Research

    Oncolytic Virus Kills Tumor Cells While Supporting T Cells

    A new type of dual-function oncolytic virus that simultaneously kills cancer cells while increasing levels of leptin to support T cells is showing promise in melanoma mouse models, researchers reported in Immunity.   

    March 11, 2020
    Research Suggests New Nurses Could Help Address the Ambulatory Staffing Issue
    Research

    Research Suggests New Nurses Could Help Address the Ambulatory Staffing Issue

    As use of ambulatory care settings continues to grow, so too does the demand for expertly trained nurses to staff them. Unfortunately, nurse staffing levels have struggled to meet the burgeoning need in ambulatory clinics throughout the country. Traditionally, undergraduates receive limited ambulatory-specific education in nursing school, leaving them unprepared to enter those settings after graduation. However, the nursing shortage complicates staffing issues, and we must develop programs to direct new graduate nurses into ambulatory oncology careers.  

    March 10, 2020
    Smoking Rates Are Low, But Here’s How They Can Be Lower
    Lung Cancer

    Smoking Rates Are Low, But Here’s How They Can Be Lower

    Although U.S. smoking rates have hit an all-time low of 14%, 34 million American adults are still considered active smokers, according to the U.S. surgeon general’s January 2020 report on smoking cessation. It’s the first new report focused directly on smoking cessation from the surgeon general’s office in 30 years. 

    March 04, 2020
    Cancer Death Rates See Largest-Ever Single-Year Drop
    American Cancer Society (ACS)

    Cancer Death Rates See Largest-Ever Single-Year Drop

    Overall U.S. cancer mortality fell 2.2% from 2016 to 2017, the largest reduction for a single year, according to the American Cancer Society’s “Cancer Statistics, 2020,” published in CA: A Cancer Journal for Clinicians.

    February 26, 2020
    HPV Vaccine Has an Indirect Benefit: Herd Immunity
    Research

    HPV Vaccine Has an Indirect Benefit: Herd Immunity

    As more people receive the human papillomavirus (HPV) vaccine to protect themselves from strains of the virus that can cause cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers, researchers are starting to see herd immunity, where even people who haven’t received the vaccine are developing fewer oral HPV infections. The findings were published in JAMA.

    February 19, 2020
    Women With Diabetes Are Less Likely to Get Cancer Screenings
    Research

    Women With Diabetes Are Less Likely to Get Cancer Screenings

    Modest differences may exist among women with diabetes compared to healthy controls when it comes to adhering to screening recommendations for breast, cervical, and colorectal cancers, according to results of a study published in Diabetologia.

    February 12, 2020
    Nurses Are Central to Lung Cancer Screening Conversations
    Cancer screening

    Nurses Are Central to Lung Cancer Screening Conversations

    Participation in clinician and patient conversations about lung cancer screening—as well as the actual screening itself—is relatively low. According to one study, only 3.9% of screening-
    eligible patients had undergone lung cancer screening. Because the screening recommendations are newer, most patients are unaware that they exist, and research highlights that only 10%–12% of the patient population has had conversations with their clinicians about it.

    February 10, 2020
    Blood Test May Show Earliest Warning of Breast Cancer
    Research

    Blood Test May Show Earliest Warning of Breast Cancer

    Identifying a panel of tumor-associated antigens and autoantibodies through a simple blood test may one day help providers diagnose the earliest stages of breast cancer, before clinical signs appear.

    February 05, 2020
    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer
    Treatments

    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer

    Pegilodecakin, an investigational, first-in-class drug currently in clinical trials, is demonstrating positive safety results and measurable responses when used in combination with pembrolizumab or nivolumab in patients with non-small cell lung cancer (NSCLC) or kidney cancer. The findings from the multicenter, phase IB study were published in Lancet Oncology.

    January 28, 2020
    FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma

    On January 23, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

    January 24, 2020
    HRSA Releases National Survey on RNs
    Health Policy

    HRSA Releases National Survey on RNs

    To better understand the demands and demographics of the larger RN community, the Health Resources Services Agency (HRSA) compiled data from the National Sample Survey of RNs (NSSRN). Released in January 2020, the report is a compendium of information and questions RNs have answered about different aspects of the life and work. The data collected since 1977 provides insight into the latest trends and future workforce projections, and HRSA uses it to help allocate workforce resources.

    January 22, 2020
    NCI Budget Boost; Ending Surprise Medical Billing; Supreme Court ACA Hearing
    Health Policy

    NCI Budget Boost; Ending Surprise Medical Billing; Supreme Court ACA Hearing

    The push and pull of budget negotiations makes for great headlines, but more important is the outcome when lawmakers finally arrive at a consensus. Earlier in December, the National Institutes of Health announced a $2.6 billion overall increase in funding, including a $297 million increase to the National Cancer Institutes (NCI), for fiscal year 2020.

    January 21, 2020
    Breast Cancer Is More Fatal in Men Than Women
    Breast cancer

    Breast Cancer Is More Fatal in Men Than Women

    Men have higher death rates than women across all stages of breast cancer, study findings reported in JAMA Oncology show. In the study, five-year overall survival after a breast cancer diagnosis was 77.6% for men and 86.4% for women.

    January 15, 2020
    What the Research Cautions About Kratom’s Opioid-Like Abuse Potential
    Complementary therapy

    What the Research Cautions About Kratom’s Opioid-Like Abuse Potential

    Kratom is a Southeast Asian tropical tree, the leaves of which have been chewed, smoked, or made as tea for their stimulant and euphoric effects. They have also been employed in traditional medicine to reduce pain and fever, to relieve diarrhea, for wound healing, and as a substitute for opium. Recently, kratom supplements have become popular in the United States for alleviating pain, improving mood, lowering anxiety, and alternative opioid withdrawal treatment.

    January 13, 2020
    Comprehensive Tobacco Treatment Helps Almost Half of Patients Quit Smoking
    Cancer risk prevention

    Comprehensive Tobacco Treatment Helps Almost Half of Patients Quit Smoking

    After nine months of follow-up, 44% of patients in a comprehensive tobacco treatment program were compliant with smoking abstinence, according to the results of a study published in JAMA Network Open.

    January 08, 2020
    Experts Recommend Tailored Exercise for All Cancer Treatment Plans
    Research

    Experts Recommend Tailored Exercise for All Cancer Treatment Plans

    Systemic use of exercise prescriptions not only lowers the risk of certain cancers but also helps to improve side effects and survival from cancer and should therefore be incorporated into cancer treatment plans, experts from the American College of Sports Medicine and 17 partner organizations said in articles published in Medicine and Science in Sports and Exercise and CA: A Cancer Journal for Clinicians.

    December 25, 2019
    Multigene Testing Is Cost Effective for All Women With Breast Cancer
    Genetics & genomics

    Multigene Testing Is Cost Effective for All Women With Breast Cancer

    According to findings from a new analysis published in JAMA Oncology, multigene testing should be expanded to all women with breast cancer and not just those with certain family histories or clinical factors.

    December 20, 2019
    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells
    Research

    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells

    Bioengineers may have found a way to use tamoxifen activated with blue light to control precisely which tissues and body areas CAR T cells attack, reducing toxicities in other parts of the body. They reported their work in ACS Synthetic Biology.

    December 18, 2019
    Head and Neck Melanoma Increases 51% in Young People
    Research

    Head and Neck Melanoma Increases 51% in Young People

    Incidence of melanoma in the head and neck areas increased 51.1% from 1995 to 2014, according to findings from a study published in JAMA Otolaryngology.

    December 11, 2019
    Research Guides the Transition of PEP Resources to ONS Guidelines
    Research

    Research Guides the Transition of PEP Resources to ONS Guidelines

    Lymphedema is one of the most common treatment side effects in patients with breast cancer. Estimates suggest that approximately 40% of all breast cancer survivors are at risk to develop lymphedema at some point in their lives. But as far back as 1998 and even before, some healthcare experts were predicting that lymphedema would be eliminated as a side effect from breast cancer treatment. Twenty-one years later, it’s still prevalent among breast cancer survivors, requiring careful management recommendations from oncology nurses to help patients live with this chronic issue.

    December 10, 2019
    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer
    Breast cancer

    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer

    Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in the Journal of Clinical Oncology.

    December 04, 2019
    NINR Acting Director; Vaping Flavor Ban; Drug Pricing 2020
    Health Policy

    NINR Acting Director; Vaping Flavor Ban; Drug Pricing 2020

    In 2018, long-time National Institute of Nursing Research (NINR) Director Patricia Grady, PhD, RN, FAAN, retired. A national search yielded no new directors, and the National Institutes of Health appointed Principal Deputy Director Lawrence Tabak, DDS, PhD, to serve as acting NINR director. However, when the director of the National Institute of Dental and Craniofacial Research announced she would retire at the end of 2019, Tabak, who previously served as the dental agency’s director, was appointed as the obvious replacement.

    November 25, 2019
    FDA Approves Acalabrutinib for CLL and SLL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Acalabrutinib for CLL and SLL

    On November 21, 2019, the U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence®) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    November 21, 2019
    What Does the Evidence Say About Reiki for Cancer?
    Complementary therapy

    What Does the Evidence Say About Reiki for Cancer?

    Reiki is a complementary health approach in which practitioners place their hands lightly on or just above a person to promote a sense of well-being. It was founded by the Japanese Buddhist and spiritual teacher Mikao Usui in the early 20th century and brought to the United States in the 1930s, where it has become increasingly popular.

    November 21, 2019
    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?
    Research

    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?

    Receiving antibiotics in the 30 days prior to starting immune checkpoint inhibitor treatment was associated with significantly reduced median overall survival, according to findings from a study published in JAMA Oncology. However, antibiotic use during treatment had no effect on survival.

    November 20, 2019
    USPSTF Updates Recommendations on Breast Cancer Prevention
    Research

    USPSTF Updates Recommendations on Breast Cancer Prevention

    Certain groups of women who are at increased risk for carrying BRCA1 or BRCA2 genes should be assessed for the need for genetic testing, and women at increased risk for breast cancer and low risk of adverse events should be offered risk-reducing medications, the U.S. Preventive Services Task Force (USPSTF) recommended.

    November 06, 2019
    New Liquid Biopsy Approach Is Accurate in Detecting Early Cancer
    Research

    New Liquid Biopsy Approach Is Accurate in Detecting Early Cancer

    A test that looks at circulating DNA rather than specific mutations is accurate in detecting 72% of early cancer cases and correctly identifying the tissue of origin in 75% of cases, researchers reported in study findings published in Nature.

    October 30, 2019
    FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer

    On October 23, 2019, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula®) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.

    October 24, 2019
    Small Study Shows T-Cell Activity in Pancreatic Cancer
    Research

    Small Study Shows T-Cell Activity in Pancreatic Cancer

    When treated with their own nonengineered T cells plus chemotherapy, six of seven patients with inoperable or metastatic pancreatic cancer showed objective responses or stable disease, according to the results of a study reported at the American Association for Cancer Research’s Immune Cell Therapies for Cancer conference in July 2019.

    October 23, 2019
    Colorectal Cancer Diagnoses Increasing in Patients Younger Than 50
    Clinical practice

    Colorectal Cancer Diagnoses Increasing in Patients Younger Than 50

    Healthcare providers are seeing increasing numbers of younger patients with colorectal cancer, and they’re being diagnosed with more advanced stages of the disease, researchers reported in study findings published in the journal Cancer.

    October 16, 2019
    CDC Estimates That 92% of HPV-Related Cancers Could Be Prevented
    Cancer prevention

    CDC Estimates That 92% of HPV-Related Cancers Could Be Prevented

    For years, the human papillomavirus (HPV) vaccine has been promoted for its potential role in cancer prevention. In a study released in August 2019 by the Centers for Disease Control and Prevention (CDC), the agency estimated that nearly 92% of all HPV-related cancers could be prevented through proper vaccination.

    October 16, 2019
    NIH HEAL Initiative Commits $945 Million to Opioid Research
    Health Policy

    NIH HEAL Initiative Commits $945 Million to Opioid Research

    Designated as a national epidemic, opioid addiction and abuse are front and center at the federal level as lawmakers work to support the discovery of new treatments and resources to curb the growing problem. The National Institutes of Health (NIH), with support from the White House, Congress, and the Department of Health and Human Services, awarded $945 million in funding for grants, contracts, and cooperative agreements across 41 states for the Helping to End Addiction Long-Term (HEAL) Initiative. Targeting novel chronic pain interventions, opioid abuse, and the addiction crisis, the HEAL Initiative will funnel funding and resources into efforts that can make an impact immediately and in the future for healthcare providers and their patients.

    October 13, 2019
    irAEs Linked to Improved Benefit From Pembrolizumab
    Immunotherapy

    irAEs Linked to Improved Benefit From Pembrolizumab

    Patients with advanced melanoma who received adjuvant therapy with pembrolizumab and subsequently developed immune-related adverse events (irAEs) saw a 63% reduced risk of recurrence, compared to 44% for those who did not develop irAEs. The study findings were presented at the 2019 American Society of Clinical Oncology annual meeting.

    October 09, 2019
    Vaccine May Boost CAR T-Cell Activity in Solid Tumors
    Research

    Vaccine May Boost CAR T-Cell Activity in Solid Tumors

    Researchers are testing a new approach using an amphiphilic cancer vaccine to deliver CAR T-cell therapy to solid tumors, and the results of preclinical studies are promising, according to findings published in the journal Science.

    September 18, 2019
    FDA Approves Combination Pembrolizumab Plus Lenvatinib
    U.S. Food and Drug Administration (FDA)

    FDA Approves Combination Pembrolizumab Plus Lenvatinib

    On September 17, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of pembrolizumab (Keytruda®) plus lenvatinib (Lenvima®) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.

    September 17, 2019
    ONS Names Debra Lyon as Incoming Oncology Nursing Forum Editor
    Press Releases

    ONS Names Debra Lyon as Incoming Oncology Nursing Forum Editor

    Oncology nursing-led research is the engine that drives practice change when caring for patients with cancer. As a standard-bearer of oncology nursing research and a veteran of nursing research publications, Debra Lyon, RN, PhD, FNP-BC, FAAN, will bring a wealth of expertise and experience to the Oncology Nursing Forum (ONF), becoming the research journal’s sixth editor effective January 1, 2020.

    September 16, 2019
    Hematologic Cancers Have Higher Long-Term Risk of Clots and Bleeding
    Research

    Hematologic Cancers Have Higher Long-Term Risk of Clots and Bleeding

    Patients with hematologic cancers have a 19% increased risk for blood clots or bleeding events even 10 years after diagnosis, according to the results of a study published in the Journal of Thrombosis and Haemostasis.

    September 11, 2019
    Evidence Supports Strategies for Better Safe Handling Practice
    Research

    Evidence Supports Strategies for Better Safe Handling Practice

    The evidence is clear: for more than 40 years, reports have confirmed that hazardous drug exposure poses significant safety risks to providers who handle many agents related to cancer treatments. Healthcare professionals experience several substantial health threats, including reproductive problems, airway and skin irritation, and cancers. Despite the potential health risks, the data are also clear: nurses routinely do not wear personal protective equipment as recommended when handling hazardous drugs.

    September 09, 2019
    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy
    Immunotherapy

    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy

    Two-year survival rates for patients with advanced melanoma increased quickly after the introduction of ipilimumab in 2011, according to an analysis published the journal Cancer.

    September 04, 2019
    Hyperthyroidism Treatment Linked  to Increased Cancer Death Risk
    Cancer risk factors

    Hyperthyroidism Treatment Linked to Increased Cancer Death Risk

    Radioactive iodine treatment for hyperthyroidism is associated with long-term risk of death from solid cancers, particularly breast cancer, according to the results of a study published in JAMA Internal Medicine. 
     

    August 21, 2019
    Ruth McCorkle Leaves Legacy of Innovation, Advancement in Oncology Nursing
    ONS News

    Ruth McCorkle Leaves Legacy of Innovation, Advancement in Oncology Nursing

    ONS member Ruth McCorkle, PhD, RN, FAPOS, FAAN, had a storied, trailblazing career in oncology nursing, leading the way to advance nursing research, patient-centered care, and educational excellence. McCorkle passed away on August 17, 2019, surrounded by her close family, leaving behind an indelible legacy to the oncology nursing profession.        

    August 20, 2019
    Healthy Finances Allow ONS to Advance Oncology Nursing and Science
    ONS News

    Healthy Finances Allow ONS to Advance Oncology Nursing and Science

    ONS wrapped up the first four months of 2019 as a financially strong organization, according to the finance reports the ONS Board of Directors received during its June 13–15 meeting. The Society’s investments are up almost 9%. It also saw an increase in ONS Congress revenue from 2018 to 2019 and will not raise Congress registration fees for 2020. A solid financial outlook allows ONS to continue to serve its members by representing and growing the profession. 
     

    August 18, 2019
    FDA Approves Fedratinib for Myelofibrosis
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fedratinib for Myelofibrosis

    On August 16, 2019, the U.S. Food and Drug Administration (FDA) approved fedratinib (Inrebic®) for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

    August 16, 2019
    FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC

    On August 15, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (RozlytrekTM) for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.

    August 16, 2019
    CAR T Cells Show Promise in Solid Tumors
    Research

    CAR T Cells Show Promise in Solid Tumors

    Two recent studies demonstrated CAR T-cell therapy activity in certain types of solid tumors, according to results presented at the American Society of Clinical Oncology annual meeting. The CAR T cells used new targets outside of the CD19 targets used for the therapy’s current approvals in leukemia and lymphoma. 
     

    August 14, 2019
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲